Overview

Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to demonstrate the superiority of SKY0402 over conventional, commercially-available bupivacaine HCl with respect to the duration of the analgesic effect achieved by a single local administration of the study drug.
Phase:
Phase 2
Details
Lead Sponsor:
Pacira Pharmaceuticals, Inc
Treatments:
Bupivacaine